Alembic Pharmaceuticals announces USFDA Final Approval for Docetaxel Injection USP Kumar Jeetendra | March 1, 2023 Alembic Pharmaceuticals Limited (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Docetaxel Injection USP, 20 mg/2 mL (10 mg/mL) Single-Dose Vial, and 80 mg/8 mL (10 mg/mL) and 160 mg/16 mL (10 mg/mL) Multiple-Dose Vials. The approved ANDA is therapeutically …
Is it safe to take omnicef while pregnant? Kumar Jeetendra | March 1, 2023 Omnicef, also known as cefdinir, is a cephalosporin antibiotic that is utilised in the treatment of a wide variety of bacterial illnesses. In the United States, the Omnicef brand name has been taken off the market. There is a generic version of Omnicef that can be purchased. Cefdinir is an extended-spectrum, semisynthetic cephalosporin that can …
CIPLA launches CIPPOINT, a point-of-care gadget for non-communicable, infectious, and other disorders. Kumar Jeetendra | January 20, 2023 Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) today announced the launch of Cippoint, a point-of-care testing device. This state-of-the-art device offers a wide range of testing parameters including cardiac markers, diabetes, infectious diseases, fertility, thyroid function, inflammation, metabolic markers, and coagulation markers. The device is CE IVD approved – …
Alembic Pharmaceuticals gets USFDA tentative approval for 100 mg Acalabrutinib capsules. Kumar Jeetendra | January 20, 2023 Alembic Pharmaceuticals Limited (Alembic) today announced that it has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA), Acalabrutinib Capsules, 100 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Calquence Capsules, 100 mg, of AstraZeneca UK Limited (AstraZeneca). Acalabrutinib Capsules are …
Sirio Pharma Successfully Completes the Acquisition of Best Formulations Kumar Jeetendra | January 9, 2023 January 9, 2023 – City of Industry, CA — Sirio Pharma Co., Ltd. (Sirio), a leading global CDMO, today announced that it has completed the acquisition of a majority stake in Best Formulations LLC, a leading contract manufacturer of Nutritional Supplements and Personal Care products based in California. With more than 35 years of experience, …
Alembic Pharmaceuticals’ Fesoterodine Fumarate Extended-Release Tablets, 4 mg and 8 mg, gain USFDA approval. Kumar Jeetendra | January 6, 2023 06th January 2023, Mumbai: Alembic Pharmaceuticals Limited (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA), Fesoterodine Fumarate Extended-Release Tablets, 4 mg and 8 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Toviaz Extended-Release …
Cipla EU to invest EUR 15 million in ETHRIS, initiating a strategic collaboration Kumar Jeetendra | December 29, 2022 Mumbai, India and Munich, Germany: December 29, 2022: Cipla Limited (BSE: 500087; NSE: CIPLA EQ) referred to as “Cipla” today announced that its wholly owned UK subsidiary, Cipla (EU) Limited (“Cipla EU”) has signed definitive agreements for equity investment of EUR 15 million in Ethris GmbH (“Ethris”), a global leader in delivering mRNAs directly to …
USFDA approves Alembic Pharmaceuticals’ Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per single-dose prefilled syringe Kumar Jeetendra | December 26, 2022 26th December, 2022, Mumbai: Alembic Pharmaceuticals Limited (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA), Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per Single-Dose Prefilled Syringe. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), …
Opportunity for Mary kay research and development: Senior Scientist R&D Compliance Kumar Jeetendra | December 21, 2022 Mary Kay’s R&D teams are enthusiastic about science. They do ongoing research on products that enable our consultants to provide their end-users with an experience of unparalleled quality and benefit. People must feel confident about themselves and their choice of Mary Kay when using our products. Our research teams travel internationally in search of innovative …
Clinithink and AstraZeneca Launch First of its Kind AI Project Aimed at Detecting Early-Stage Lung Cancer Kumar Jeetendra | December 15, 2022 Clinithink, the company that has developed the world’s first Healthcare AI capable of truly understanding unstructured medical notes, has partnered with AstraZeneca Oncology UK in a new project that aims to find patients with lung cancer at an early stage where treatment can be more effective. The project announced today hopes to demonstrate potential savings …
ENTOD Pharmaceuticals Launches Week-Long Initiative to Raise Awareness and Recognise the Growing Threat of Myopia in Children Kumar Jeetendra | November 14, 2022 In an effort to bring awareness of the myopia epidemic in India and the growing number of myopic children, ENTOD Pharmaceuticals is supporting a week-long Myopia Awareness Campaign organised by ENTOD Eye Health Foundation in association with the Strabismus and Pediatric Ophthalmological Society of India (SPOSI) from November 14-20, observes National Myopia Week in India. …
IOL Chemicals and Pharmaceuticals receives EDQM certification to supply Pantoprazole Sodium Sesquihydrate API in European market Kumar Jeetendra | November 7, 2022 IOL Chemicals and Pharmaceuticals Limited (IOL), a leading manufacturer of pharmaceutical (APIs) and specialty chemicals, announced receiving EDQM certification to supply Pantoprazole Sodium Sesquihydrate API across European market. Pantoprazole Sodium Sesquihydrate are proton pump inhibitors used in drugs to suppress the gastric acid secretion. The company started production of Pantoprazole Sodium Sesquihydrate in Q3 FY …
